+ − Summary
+ − Full Texts (3)
+ − Actions (30)
- Governor Approved
- Effective Date January 1, 2023
- Public Act . . . . . . . . . 102-1073
- Sent to the Governor
- Passed Both Houses
- Third Reading - Passed; 054-000-000
- Second Reading
- Placed on Calendar Order of 3rd Reading March 25, 2022
- Do Pass Insurance; 011-000-000
- Placed on Calendar Order of 2nd Reading
- Assigned to Insurance
- Arrive in Senate
- Placed on Calendar Order of First Reading
- Chief Senate Sponsor Sen. Emil Jones, III
- First Reading
- Referred to Assignments
- Third Reading - Short Debate - Passed 108-000-000
- Second Reading - Short Debate
- House Floor Amendment No. 1 Adopted
- Placed on Calendar Order of 3rd Reading - Short Debate
- House Floor Amendment No. 1 Rules Refers to Insurance Committee
- House Floor Amendment No. 1 Recommends Be Adopted Insurance Committee; 010-000-000
- House Floor Amendment No. 1 Filed with Clerk by Rep. La Shawn K. Ford
- House Floor Amendment No. 1 Referred to Rules Committee
- Placed on Calendar 2nd Reading - Short Debate
- Do Pass / Short Debate Insurance Committee; 012-004-000
- Assigned to Insurance Committee
- First Reading
- Referred to Rules Committee
- Filed with the Clerk by Rep. La Shawn K. Ford
+ − Adopted Amendment
House Amendment 001
Replaces everything after the enacting clause with the provisions of the introduced bill with the following changes. Provides that a group policy of accident and health insurance that provides coverage for hospital or medical treatment or services for illness on an expense-incurred basis and is amended, delivered, issued, or renewed after January 1, 2024 (rather than the effective date of the amendatory Act) shall provide coverage, without imposing a deductible, coinsurance, copayment, or any other cost-sharing requirement, for specified methods of cancer testing. Specifies that the provisions do not apply to coverage of prostate cancer screenings to the extent such coverage would disqualify a high-deductible health plan from eligibility for a health savings account under the Internal Revenue Code. Defines "prostate cancer screening" to include medically necessary subsequent follow-up testing as directed by a health care provider (rather than subsequent follow-up testing as directed by a health care provider).
